FMR LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 131 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2017. The put-call ratio across all filers is 1.26 and the average weighting 0.7%.

Quarter-by-quarter ownership
FMR LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$1,000
-50.0%
4,2000.0%0.00%
Q3 2018$2,000
-100.0%
4,200
-99.9%
0.00%
-100.0%
Q1 2018$13,907,000
-35.8%
5,968,515
-21.7%
0.00%
-33.3%
Q4 2017$21,649,000
-15.4%
7,622,752
-14.8%
0.00%0.0%
Q3 2017$25,582,000
+6.2%
8,944,852
-8.3%
0.00%0.0%
Q2 2017$24,094,000
-52.7%
9,754,460
-30.8%
0.00%
-50.0%
Q1 2017$50,914,000
-25.6%
14,103,611
-27.0%
0.01%
-33.3%
Q4 2016$68,418,000
+23.0%
19,327,111
+40.3%
0.01%
+28.6%
Q3 2016$55,637,000
-8.7%
13,771,516
-0.8%
0.01%
-12.5%
Q2 2016$60,922,000
+9.9%
13,877,416
-5.4%
0.01%0.0%
Q1 2016$55,437,000
-76.1%
14,665,813
-0.9%
0.01%
-74.2%
Q4 2015$232,015,000
+52.0%
14,796,853
+2.2%
0.03%
+40.9%
Q3 2015$152,594,000
-59.0%
14,477,611
-2.0%
0.02%
-54.2%
Q2 2015$372,553,000
-8.0%
14,772,123
+1.7%
0.05%
-7.7%
Q1 2015$404,851,000
+65.1%
14,526,417
+8.1%
0.05%
+62.5%
Q4 2014$245,250,000
+56.9%
13,438,365
+11.4%
0.03%
+52.4%
Q3 2014$156,305,000
-20.5%
12,060,567
+0.1%
0.02%
-19.2%
Q2 2014$196,727,000
-6.7%
12,054,373
+1.0%
0.03%
-10.3%
Q1 2014$210,900,000
-28.3%
11,935,499
-1.8%
0.03%
-31.0%
Q4 2013$294,329,000
-30.4%
12,157,327
+1.8%
0.04%
-35.4%
Q3 2013$423,033,000
+480.5%
11,939,942
+155.8%
0.06%
+441.7%
Q2 2013$72,871,0004,668,2210.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2017
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,000$3,096,000100.00%
TSP Capital Management Group, LLC 698,674$1,549,0000.79%
Meditor Group Ltd 6,312,700$2,847,0000.61%
Telemetry Investments, L.L.C. 186,200$84,0000.04%
GSA CAPITAL PARTNERS LLP 1,270,500$573,0000.03%
Benchmark Capital Advisors 53,400$24,0000.02%
BOENNING & SCATTERGOOD, INC. 80,150$36,0000.01%
NJ State Employees Deferred Compensation Plan 80,000$36,0000.01%
Centiva Capital, LP 121,720$55,0000.01%
Overbrook Management Corp 48,611$22,0000.00%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders